Learn how to finance your innovative idea!

Join Dr. Jom Aw, the Biosciences Business Entrepreneur-In-Residence, and Jamie Stiff, partner with Genesys Capital for a 2 hour workshop designed for researchers and students who want to learn how to commercialise an idea. The focus will be on financing in the life science sector, however individuals from any sector are welcome, and will take away valuable insight on raising cash to commercialise a technology based opportunity.   Read more of this post

L’union fait la cure/Connect for the Cure

(English message follows)

Le Réseau de transfert de technologie d’Ottawa (RTTO) et PARTEQ Innovations présente un forum d’innovation en recherche sur le cancer de l’est de l’Ontario qui permettra aux chercheurs en sciences fondamentales et aux cliniciens-chercheurs de l’Université d’Ottawa, de l’Institut de recherche de l’Hôpital d’Ottawa, du Centre hospitalier pour enfants de l’est de l’Ontario (CHEO), de l’Université Queen’s et du Queen’s Cancer Research Institute de joindre leurs forces dans les domaines de la recherche translationnelle, de la gestion des essais cliniques, des marqueurs biologiques et des virus oncolytiques. Read more of this post

Learn how to finance your innovative idea!

Join Dr. Jom Aw, the Biosciences Business Entrepreneur-In-Residence, and Jamie Stiff, partner with Genesys Capital for a 2 hour workshop designed for researchers and students who want to learn how to commercialise an idea. The focus will be on financing in the life science sector, however individuals from any sector are welcome, and will take away valuable insight on raising cash to commercialise a technology based opportunity. Read more of this post

eSight: startup to watch in 2010

eSight Corporation, one of OTTN’s spin-off companies, was featured in the Ottawa Business Journal as one of Ottawa’s cream of the crop new startups to keep an eye on in 2010.  The company’s lead product  is a lightweight, sunglasses-like device with built-in video camera and display screens.  eSight chairman Dan Mathers says the product, which is currently undergoing patient trials with an anticipated commerical debut in fall 2010,  gives Read more of this post